{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:59:17Z","timestamp":1792720757868,"version":"4.5.0"},"reference-count":43,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1084,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Ophthalmol"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1111\/j.1755-3768.2012.02518.x","type":"journal-article","created":{"date-parts":[[2012,9,12]],"date-time":"2012-09-12T11:59:18Z","timestamp":1347451158000},"page":"604-609","source":"Crossref","is-referenced-by-count":60,"title":["The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?"],"prefix":"10.1111","volume":"91","author":[{"given":"Wing L.","family":"Ho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilda","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Yau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,9,12]]},"reference":[{"key":"10.1111\/j.1755-3768.2012.02518.x-BIB1|cit1","first-page":"86","article-title":"Erlotinib: new drug. Non small-cell lung cancer: like gefitinib, no established advantage","volume":"15","year":"2006","journal-title":"Prescrire Int"},{"key":"10.1111\/j.1755-3768.2012.02518.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1001\/archneur.63.10.1475","article-title":"Reversible posterior leukoencephalopathy syndrome after bevacizumab\/FOLFIRI regimen for metastatic colon cancer","volume":"63","author":"Allen","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1111\/j.1755-3768.2012.02518.x-BIB3|cit3","first-page":"108","article-title":"A randomised trial evaluating Bevacizumab as adjuvant therapy following resection of AJCC stage IIB, IIC and III cutaneous melanoma: an update","volume":"2","author":"Biswas","year":"2008","journal-title":"Ecancermedicalscience"},{"key":"10.1111\/j.1755-3768.2012.02518.x-BIB4|cit4","first-page":"1599","article-title":"Imatinib induces apoptosis by inhibiting PDGF- but not insulin-induced PI 3-kinase\/Akt survival signaling in RGC-5 retinal ganglion cells","volume":"15","author":"Biswas","year":"2009","journal-title":"Mol Vis"},{"key":"10.1111\/j.1755-3768.2012.02518.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2010.29.5865","article-title":"Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy","volume":"29","author":"Burris","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1755-3768.2012.02518.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1445-5994.2009.01908.x","article-title":"Reversible posterior leucoencephalopathy syndrome associated with sunitinib","volume":"39","author":"Chen","year":"2009","journal-title":"Intern Med J"},{"key":"10.1111\/j.1755-3768.2012.02518.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2010.28.15_suppl.2504","article-title":"First-in-human phase I safety, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the oral MEK inhibitor AS703026 (two regimens [R]) in patients (pts) with advanced solid tumors","volume":"28","author":"Delord","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1755-3768.2012.02518.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors","volume":"347","author":"Demetri","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1755-3768.2012.02518.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.hoc.2008.11.003","article-title":"Ocular side effects associated with imatinib mesylate and perifosine for gastrointestinal stromal tumor","volume":"23","author":"Dogan","year":"2009","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1111\/j.1755-3768.2012.02518.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/02841860310006038","article-title":"Epidermal growth factor receptor inhibition induces trichomegaly","volume":"42","author":"Dueland","year":"2003","journal-title":"Acta Oncol"},{"key":"10.1111\/j.1755-3768.2012.02518.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/cncr.10729","article-title":"Severe periorbital edema secondary to STI571 (Gleevec)","volume":"95","author":"Esmaeli","year":"2002","journal-title":"Cancer"},{"key":"10.1111\/j.1755-3768.2012.02518.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/sj.eye.6701315","article-title":"Periorbital oedema and epiphora as ocular side effects of imatinib mesylate (Gleevec)","volume":"18","author":"Esmaeli","year":"2004","journal-title":"Eye (Lond)"},{"key":"10.1111\/j.1755-3768.2012.02518.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/ICO.0b013e318166f483","article-title":"Persisting corneal erosion under cetuximab (Erbitux) treatment (epidermal growth factor receptor antibody)","volume":"27","author":"Foerster","year":"2008","journal-title":"Cornea"},{"key":"10.1111\/j.1755-3768.2012.02518.x-BIB14|cit14","first-page":"269","article-title":"[Topical application of EGF for the therapy of persisting corneal erosion under cetuximab treatment]","volume":"105","author":"Forster","year":"2008","journal-title":"Ophthalmologe"},{"key":"10.1111\/j.1755-3768.2012.02518.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1089\/108076803322279426","article-title":"Ocular side-effects associated with imatinib mesylate (Gleevec)","volume":"19","author":"Fraunfelder","year":"2003","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1111\/j.1755-3768.2012.02518.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1056\/NEJMc052954","article-title":"Reversible posterior leukoencephalopathy syndrome and bevacizumab","volume":"354","author":"Glusker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1755-3768.2012.02518.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10792-007-9038-9","article-title":"Imatinib-induced optic neuritis in a patient of chronic myeloid leukemia","volume":"27","author":"Govind Babu","year":"2007","journal-title":"Int Ophthalmol"},{"key":"10.1111\/j.1755-3768.2012.02518.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.ajo.2008.09.022","article-title":"The inhibitory effects of trastuzumab on corneal neovascularization","volume":"147","author":"Guler","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1111\/j.1755-3768.2012.02518.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/jco.2010.28.15_suppl.2503","article-title":"Safety and efficacy results from the first-in-human study of the oral MEK 1\/2 inhibitor GSK1120212","volume":"28","author":"Infante","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1755-3768.2012.02518.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/ICO.0b013e31818fdbc6","article-title":"Persistent corneal epithelial defect associated with erlotinib treatment","volume":"28","author":"Johnson","year":"2009","journal-title":"Cornea"},{"key":"10.1111\/j.1755-3768.2012.02518.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/ICO.0b013e3181b55cd8","article-title":"Perifosine-related rapidly progressive corneal ring infiltrate","volume":"29","author":"Keenan","year":"2010","journal-title":"Cornea"},{"key":"10.1111\/j.1755-3768.2012.02518.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/sj.eye.6703092","article-title":"Histologic studies of the intraocular toxicity of imatinib mesylate in rabbits","volume":"22","author":"Kitzmann","year":"2008","journal-title":"Eye (Lond)"},{"key":"10.1111\/j.1755-3768.2012.02518.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/01.cco.0000228734.32261.62","article-title":"Adverse effects of the humanized antibodies used as cancer therapeutics","volume":"18","author":"Klastersky","year":"2006","journal-title":"Curr Opin Oncol"},{"key":"10.1111\/j.1755-3768.2012.02518.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s10384-008-0561-7","article-title":"Optic disc edema as a possible complication of Imatinib mesylate (Gleevec)","volume":"52","author":"Kwon","year":"2008","journal-title":"Jpn J Ophthalmol"},{"key":"10.1111\/j.1755-3768.2012.02518.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/IOP.0b013e31802d9802","article-title":"Erlotinib-associated trichomegaly","volume":"23","author":"Lane","year":"2007","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"10.1111\/j.1755-3768.2012.02518.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/j.jcrs.2005.10.029","article-title":"Imatinib as a cause of cystoid macular edema following uneventful phacoemulsification surgery","volume":"31","author":"Masood","year":"2005","journal-title":"J Cataract Refract Surg"},{"key":"10.1111\/j.1755-3768.2012.02518.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2147\/OPTH.S8521","article-title":"Periorbital edema secondary to imatinib mesylate","volume":"4","author":"McClelland","year":"2010","journal-title":"Clin Ophthalmol"},{"key":"10.1111\/j.1755-3768.2012.02518.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2354.2006.00763.x","article-title":"Eye complications of cetuximab therapy","volume":"16","author":"Melichar","year":"2007","journal-title":"Eur J Cancer Care (Engl)"},{"key":"10.1111\/j.1755-3768.2012.02518.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1600-0420.2007.00926.x","article-title":"Acute retinal pigment epithelial tear in the untreated fellow eye following repeated bevacizumab (Avastin) injections","volume":"85","author":"Mennel","year":"2007","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1111\/j.1755-3768.2012.02518.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/IOP.0b013e31802d97f0","article-title":"Newly recognized ocular side effects of erlotinib","volume":"23","author":"Methvin","year":"2007","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"10.1111\/j.1755-3768.2012.02518.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1365-2125.2010.03893.x","article-title":"Reversible posterior leucoencephalopathy syndrome in an elderly male on sunitinib therapy","volume":"71","author":"Padhy","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/j.1755-3768.2012.02518.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/01676830802222936","article-title":"Trichomegaly induced by erlotinib","volume":"27","author":"Papadopoulos","year":"2008","journal-title":"Orbit"},{"key":"10.1111\/j.1755-3768.2012.02518.x-BIB33|cit33","first-page":"2929","article-title":"Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors","volume":"61","author":"Pietras","year":"2001","journal-title":"Cancer Res"},{"key":"10.1111\/j.1755-3768.2012.02518.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/BF02983993","article-title":"Conjunctival hemorrhagic events associated with imatinib mesylate","volume":"86","author":"Radaelli","year":"2007","journal-title":"Int J Hematol"},{"key":"10.1111\/j.1755-3768.2012.02518.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1158\/1078-0432.CCR-08-0333","article-title":"Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway","volume":"14","author":"Sebolt-Leopold","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1111\/j.1755-3768.2012.02518.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S1470-2045(11)70232-7","article-title":"Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis","volume":"12","author":"Shaw","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1111\/j.1755-3768.2012.02518.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1212\/WNL.0b013e3181c3fd00","article-title":"Optic neuropathy in patients with glioblastoma receiving bevacizumab","volume":"73","author":"Sherman","year":"2009","journal-title":"Neurology"},{"key":"10.1111\/j.1755-3768.2012.02518.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ophtha.2007.11.016","article-title":"Ulcerative keratitis in gastrointestinal stromal tumor patients treated with perifosine","volume":"115","author":"Shome","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1111\/j.1755-3768.2012.02518.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1001\/archopht.117.4.493","article-title":"Human conjunctival mast cells: expression of Fc epsilonRI, c-kit, ICAM-1, and IgE","volume":"117","author":"Stahl","year":"1999","journal-title":"Arch Ophthalmol"},{"key":"10.1111\/j.1755-3768.2012.02518.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/jnci\/dji104","article-title":"Ocular toxicity related to cetuximab monotherapy in an advanced colorectal cancer patient","volume":"97","author":"Tonini","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/j.1755-3768.2012.02518.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/sj.eye.6701630","article-title":"Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (\u2018Iressa\u2019, ZD1839) in Phase I and II clinical trials","volume":"19","author":"Tullo","year":"2005","journal-title":"Eye (Lond)"},{"key":"10.1111\/j.1755-3768.2012.02518.x-BIB42|cit42","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1365-2230.2008.02842.x","article-title":"Trichomegaly of the eyelashes following treatment with cetuximab","volume":"34","author":"Vaccaro","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"10.1111\/j.1755-3768.2012.02518.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jaad.2009.02.023","article-title":"Cetuximab-induced hypertrichosis of the scalp and eyelashes","volume":"62","author":"Vano-Galvan","year":"2010","journal-title":"J Am Acad Dermatol"}],"container-title":["Acta Ophthalmologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1755-3768.2012.02518.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1755-3768.2012.02518.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T11:38:02Z","timestamp":1625571482000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1755-3768.2012.02518.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,12]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,11]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1755-3768.2012.02518.x","relation":{},"ISSN":["1755-375X"],"issn-type":[{"value":"1755-375X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9,12]]}}}